PharmGKB summary: isoniazid pathway, pharmacokinetics

Pharmacogenet Genomics. 2016 Sep;26(9):436-44. doi: 10.1097/FPC.0000000000000232.

Authors

Daniel J Klein¹, Sotiria Boukouvala, Ellen M McDonagh, Scott R Shuldiner, Nicola Laurieri, Caroline F Thorn, Russ B Altman, Teri E Klein

Affiliation

¹ Departments of aGenetics bBioengineering, Stanford University, Stanford cKeck School of Medicine of University of Southern California, Los Angeles, California, USA dDepartment of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece eDepartment of Pharmacology, University of Oxford, Oxford, UK.

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Humans
Isoniazid / chemistry*
Isoniazid / therapeutic use
Mycobacterium tuberculosis / drug effects
Mycobacterium tuberculosis / genetics
Mycobacterium tuberculosis / pathogenicity
Pharmacogenetics*
Tuberculosis / drug therapy*

Substances

Isoniazid

Grant support

R24 GM061374/GM/NIGMS NIH HHS/United States